Shanxi C&Y Pharmaceutical Group Co Ltd
ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, respiratory drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, comme… Read more
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) - Net Assets
Latest net assets as of September 2025: CN¥577.09 Million CNY
Based on the latest financial reports, Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has net assets worth CN¥577.09 Million CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.55 Billion) and total liabilities (CN¥972.67 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥577.09 Million |
| % of Total Assets | 37.24% |
| Annual Growth Rate | 11.38% |
| 5-Year Change | -31.45% |
| 10-Year Change | -31.44% |
| Growth Volatility | 70.05 |
Shanxi C&Y Pharmaceutical Group Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Shanxi C&Y Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual net assets of Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥598.18 Million | -23.16% |
| 2023-12-31 | CN¥778.43 Million | +6.68% |
| 2022-12-31 | CN¥729.68 Million | -2.00% |
| 2021-12-31 | CN¥744.58 Million | -14.67% |
| 2020-12-31 | CN¥872.61 Million | -6.43% |
| 2019-12-31 | CN¥932.60 Million | +0.15% |
| 2018-12-31 | CN¥931.24 Million | -4.11% |
| 2017-12-31 | CN¥971.17 Million | +1.71% |
| 2016-12-31 | CN¥954.85 Million | +9.44% |
| 2015-12-31 | CN¥872.50 Million | +5.99% |
| 2014-12-31 | CN¥823.16 Million | +7.30% |
| 2013-12-31 | CN¥767.16 Million | +17.81% |
| 2012-12-31 | CN¥651.17 Million | +12.04% |
| 2011-12-31 | CN¥581.17 Million | +288.52% |
| 2010-12-31 | CN¥149.59 Million | +27.20% |
| 2009-12-31 | CN¥117.60 Million | +10.22% |
| 2008-12-31 | CN¥106.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanxi C&Y Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7677.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | CN¥248.32 Million | 72.40% |
| Other Components | CN¥335.84 Million | 97.91% |
| Total Equity | CN¥343.00 Million | 100.00% |
Shanxi C&Y Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Shanxi C&Y Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maxvision Technology Corp
SHE:002990
|
$348.09 Million |
|
SMO ClinPlus Co. Ltd.
SHE:301257
|
$348.10 Million |
|
Zhuhai Huajin Capital Co Ltd
SHE:000532
|
$348.17 Million |
|
eClerx Services Limited
NSE:ECLERX
|
$348.21 Million |
|
Shandong Meichen Science & Technology Co Ltd
SHE:300237
|
$347.84 Million |
|
Hubei Sanxia New Building Materials Co Ltd
SHG:600293
|
$347.71 Million |
|
Gansu Dayu Water saving Group
SHE:300021
|
$347.65 Million |
|
Bomesc Offshore Engineering Co
SHG:603727
|
$347.54 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanxi C&Y Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 600,132,522 to 342,998,882, a change of -257,133,640 (-42.8%).
- Net income of 42,190,119 contributed positively to equity growth.
- Dividend payments of 12,321,406 reduced retained earnings.
- Share repurchases of 1,659,364 reduced equity.
- Other factors decreased equity by 285,342,989.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥42.19 Million | +12.3% |
| Dividends Paid | CN¥12.32 Million | -3.59% |
| Share Repurchases | CN¥1.66 Million | -0.48% |
| Other Changes | CN¥-285.34 Million | -83.19% |
| Total Change | CN¥- | -42.85% |
Book Value vs Market Value Analysis
This analysis compares Shanxi C&Y Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.79x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 15.23x to 8.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.80 | CN¥12.12 | x |
| 2009-12-31 | CN¥0.82 | CN¥12.12 | x |
| 2010-12-31 | CN¥1.04 | CN¥12.12 | x |
| 2011-12-31 | CN¥3.65 | CN¥12.12 | x |
| 2012-12-31 | CN¥3.05 | CN¥12.12 | x |
| 2013-12-31 | CN¥3.17 | CN¥12.12 | x |
| 2014-12-31 | CN¥3.97 | CN¥12.12 | x |
| 2015-12-31 | CN¥4.77 | CN¥12.12 | x |
| 2016-12-31 | CN¥3.76 | CN¥12.12 | x |
| 2017-12-31 | CN¥3.92 | CN¥12.12 | x |
| 2018-12-31 | CN¥3.84 | CN¥12.12 | x |
| 2019-12-31 | CN¥3.92 | CN¥12.12 | x |
| 2020-12-31 | CN¥3.22 | CN¥12.12 | x |
| 2021-12-31 | CN¥2.59 | CN¥12.12 | x |
| 2022-12-31 | CN¥2.43 | CN¥12.12 | x |
| 2023-12-31 | CN¥2.48 | CN¥12.12 | x |
| 2024-12-31 | CN¥1.38 | CN¥12.12 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanxi C&Y Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.30%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.98%
- • Asset Turnover: 0.55x
- • Equity Multiplier: 4.51x
- Recent ROE (12.30%) is above the historical average (2.54%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 12.22% | 6.40% | 0.91x | 2.10x | CN¥2.36 Million |
| 2009 | 24.57% | 11.86% | 0.94x | 2.21x | CN¥17.14 Million |
| 2010 | 32.08% | 15.02% | 1.14x | 1.88x | CN¥33.03 Million |
| 2011 | 6.08% | 11.37% | 0.44x | 1.21x | CN¥-22.77 Million |
| 2012 | 4.33% | 7.14% | 0.44x | 1.39x | CN¥-33.83 Million |
| 2013 | 4.44% | 5.28% | 0.47x | 1.79x | CN¥-33.89 Million |
| 2014 | 6.43% | 6.27% | 0.55x | 1.85x | CN¥-22.76 Million |
| 2015 | 2.91% | 3.35% | 0.52x | 1.66x | CN¥-55.70 Million |
| 2016 | 3.73% | 4.04% | 0.52x | 1.77x | CN¥-50.72 Million |
| 2017 | 2.64% | 2.31% | 0.62x | 1.85x | CN¥-60.29 Million |
| 2018 | 0.91% | 0.64% | 0.76x | 1.87x | CN¥-72.67 Million |
| 2019 | 0.65% | 0.47% | 0.63x | 2.21x | CN¥-76.29 Million |
| 2020 | -38.18% | -30.94% | 0.47x | 2.62x | CN¥-331.08 Million |
| 2021 | -15.51% | -9.83% | 0.61x | 2.59x | CN¥-150.38 Million |
| 2022 | -20.62% | -14.30% | 0.52x | 2.76x | CN¥-176.07 Million |
| 2023 | 4.20% | 3.15% | 0.56x | 2.39x | CN¥-34.82 Million |
| 2024 | 12.30% | 4.98% | 0.55x | 4.51x | CN¥7.89 Million |
Industry Comparison
This section compares Shanxi C&Y Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $5,061,893,866
- Average return on equity (ROE) among peers: 4.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanxi C&Y Pharmaceutical Group Co Ltd (300254) | CN¥577.09 Million | 12.22% | 1.69x | $347.93 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $608.50 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.29 Billion | 4.72% | 1.33x | $324.94 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $11.33 Billion | 18.40% | 0.22x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.30 Billion | 13.53% | 1.39x | $1.92 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $525.21 Million | 17.84% | 0.75x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $4.63 Billion | -3.44% | 1.33x | $704.71 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $268.78 Million | 10.37% | 0.50x | $325.99 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.07 Billion | 2.59% | 1.71x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $22.44 Billion | 6.25% | 0.15x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $3.91 Billion | 12.94% | 0.18x | $777.45 Million |